Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shire's Fosrenol Is Boosting ESRD Market, Not Switching Renagel Patients, Genzyme Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Renagel remains healthy despite competition from Shire's phosphate-control agent, the company maintains. Genzyme continues to see opportunities for its end-stage renal disease therapy with Medicare Part D.
Advertisement

Related Content

Fosrenol Approved In Higher Dose Formulation
Fosrenol Approved In Higher Dose Formulation
Genzyme Expands Renal Disease Business With $600 Mil. Acquisition Of Bone Care
Genzyme Expands Renal Disease Business With $600 Mil. Acquisition Of Bone Care
Shire/TKT Merger Deal Focuses On Dynepo Rights In Europe
Shire's Fosrenol Gets FDA Nod, Will Be Available By Year-End
Shire's Fosrenol Gets FDA Nod, Will Be Available By Year-End
Genzyme Providing Renagel At Discount To Seniors Ahead Of Medicare Rx

Topics

Advertisement
UsernamePublicRestriction

Register

PS062052

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel